AR056573A1 - Forma cristalina delta del clohidrato de ivabradina,un procedimiento para su preparacion,composiciones farmaceuticas que la contienen y usos en trastornos cardiovasculares. - Google Patents

Forma cristalina delta del clohidrato de ivabradina,un procedimiento para su preparacion,composiciones farmaceuticas que la contienen y usos en trastornos cardiovasculares.

Info

Publication number
AR056573A1
AR056573A1 ARP060104434A ARP060104434A AR056573A1 AR 056573 A1 AR056573 A1 AR 056573A1 AR P060104434 A ARP060104434 A AR P060104434A AR P060104434 A ARP060104434 A AR P060104434A AR 056573 A1 AR056573 A1 AR 056573A1
Authority
AR
Argentina
Prior art keywords
expressed
clohydrate
ivabradine
procedure
preparation
Prior art date
Application number
ARP060104434A
Other languages
English (en)
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36588996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056573(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR056573A1 publication Critical patent/AR056573A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forma cristalina deltad del clorhidrato de ivabradina de formula (1) caracterizada por el siguiente diagrama de difraccion X sobre polvo, medido en un difractometro PANanytical X'Pert Pro con un detector X'Celerator, y expresado en términos de posicion de rayo (ángulo de Bragg 2 theta, expresado en grados), de altura de rayo (expresada en cuentas), de área de rayo (expresada en cuentas por grados), de ancho de rayos a media altura (ôFWHMö, expresada en grados) y de distancia interplanar d (expresada en L): ver cuadro (1).
ARP060104434A 2005-10-11 2006-10-09 Forma cristalina delta del clohidrato de ivabradina,un procedimiento para su preparacion,composiciones farmaceuticas que la contienen y usos en trastornos cardiovasculares. AR056573A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0510354A FR2891827B1 (fr) 2005-10-11 2005-10-11 Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
AR056573A1 true AR056573A1 (es) 2007-10-10

Family

ID=36588996

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104434A AR056573A1 (es) 2005-10-11 2006-10-09 Forma cristalina delta del clohidrato de ivabradina,un procedimiento para su preparacion,composiciones farmaceuticas que la contienen y usos en trastornos cardiovasculares.

Country Status (32)

Country Link
US (3) US7384932B2 (es)
EP (2) EP1958937A1 (es)
JP (1) JP2007112797A (es)
KR (1) KR20070040310A (es)
CN (1) CN1948293A (es)
AP (1) AP2185A (es)
AR (1) AR056573A1 (es)
AU (1) AU2006228028B2 (es)
BR (1) BRPI0604253A (es)
CA (1) CA2564369C (es)
CO (1) CO5840253A1 (es)
CR (1) CR8647A (es)
EA (1) EA010286B1 (es)
EC (1) ECSP066914A (es)
FR (1) FR2891827B1 (es)
GE (1) GEP20094654B (es)
GT (1) GT200600448A (es)
IL (1) IL178545A (es)
MA (1) MA28625B1 (es)
MX (1) MXPA06011767A (es)
MY (1) MY140490A (es)
NI (1) NI200600240A (es)
NO (1) NO20064588L (es)
NZ (1) NZ550436A (es)
PE (1) PE20070547A1 (es)
SA (1) SA06270371B1 (es)
SG (1) SG131857A1 (es)
TW (1) TW200800221A (es)
UA (1) UA90266C2 (es)
UY (1) UY29856A1 (es)
WO (1) WO2007042657A1 (es)
ZA (1) ZA200608404B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
EP2097383B1 (en) 2006-11-30 2012-02-08 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
KR101478855B1 (ko) 2007-05-30 2015-01-02 인드-스위프트 래버러토리즈 리미티드 이바브라딘 히드로클로라이드 및 그의 다형태의 제조방법
CN102264689B (zh) 2008-12-22 2014-12-31 新梅斯托克尔卡公司 制备伊伐布雷定的方法
CN101768117B (zh) * 2008-12-29 2014-05-07 北京德众万全药物技术开发有限公司 一种盐酸伊伐布雷定晶型及其制备方法
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
US8270169B2 (en) 2009-03-24 2012-09-18 Raytheon Company Translating hinge
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
EA201290772A1 (ru) 2010-02-12 2013-02-28 КРКА, д.д., НОВО МЕСТО Новые формы ивабрадина гидрохлорида
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
CN102731400A (zh) * 2011-04-11 2012-10-17 山东新时代药业有限公司 一种盐酸伊伐布雷定的新晶型、制备方法及其在制备药物组合物中的用途
WO2013017582A1 (en) 2011-08-02 2013-02-07 Sandoz Ag Acetone solvate of ivabradine hydrochloride
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
EP2589594A1 (en) * 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
EP2780327A1 (en) * 2011-11-14 2014-09-24 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
CN103012269B (zh) * 2013-01-05 2014-08-13 江苏宇田生物医药科技有限公司 一种盐酸伊伐布雷定晶型c及其制备方法
EP2948432B1 (en) 2013-01-24 2018-09-19 Synthon BV Process for making ivabradine
EP2781509B2 (en) 2013-03-19 2023-06-14 Chemo Research, S.L. New polymorph of ivabradine hydrochloride and method for its preparation
CZ2013767A3 (cs) * 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
WO2015001133A1 (en) 2013-12-12 2015-01-08 Synthon B.V. Pharmaceutical composition comprising amorphous ivabradine
PT2774606T (pt) 2014-02-14 2019-05-06 Synthon Bv Composição farmacêutica compreendendo polimorfo de cloridrato de ivabradina iv
CN103880748B (zh) * 2014-04-03 2015-09-16 南京正大天晴制药有限公司 一种盐酸伊伐布雷定结构类似物及其制备方法和应用
CZ2014478A3 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2016102423A1 (en) 2014-12-22 2016-06-30 Ratiopharm Gmbh Composition comprising ivabradine in a dissolved form
CN105503726B (zh) * 2015-12-30 2019-07-30 浙江美诺华药物化学有限公司 伊伐布雷定盐酸盐晶型变体delta-d的制备方法
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
CN107200710A (zh) * 2017-05-22 2017-09-26 苏州华健瑞达医药技术有限公司 盐酸伊伐布雷定新晶型、制备方法及含有其的组合物
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3418270A1 (de) * 1984-05-17 1985-11-21 Dr. Karl Thomae Gmbh, 7950 Biberach Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9017453D0 (en) 1990-08-09 1990-09-26 Mcivor Robert C Fluid additive regulating apparatus
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
IL178545A (en) 2017-04-30
PE20070547A1 (es) 2007-07-07
US20070082886A1 (en) 2007-04-12
GEP20094654B (en) 2009-03-25
MXPA06011767A (es) 2007-04-10
CN1948293A (zh) 2007-04-18
EP1958937A1 (fr) 2008-08-20
NI200600240A (es) 2008-01-10
ECSP066914A (es) 2007-05-30
AU2006228028B2 (en) 2011-08-25
JP2007112797A (ja) 2007-05-10
US7879841B2 (en) 2011-02-01
SG131857A1 (en) 2007-05-28
US20090318418A1 (en) 2009-12-24
BRPI0604253A (pt) 2007-08-21
US20080227771A1 (en) 2008-09-18
CA2564369C (fr) 2010-06-15
CO5840253A1 (es) 2007-12-31
MY140490A (en) 2009-12-31
NZ550436A (en) 2007-12-21
SA06270371B1 (ar) 2010-03-08
MA28625B1 (fr) 2007-06-01
US7384932B2 (en) 2008-06-10
UY29856A1 (es) 2006-11-30
IL178545A0 (en) 2007-02-11
KR20070040310A (ko) 2007-04-16
AU2006228028A1 (en) 2007-04-26
AP2185A (en) 2010-12-30
EA200601661A1 (ru) 2007-04-27
AP2006003757A0 (en) 2006-10-31
UA90266C2 (ru) 2010-04-26
NO20064588L (no) 2007-04-12
FR2891827A1 (fr) 2007-04-13
TW200800221A (en) 2008-01-01
GT200600448A (es) 2007-05-21
ZA200608404B (en) 2008-06-25
EA010286B1 (ru) 2008-08-29
WO2007042657A1 (fr) 2007-04-19
CR8647A (es) 2007-06-08
EP1775287A1 (fr) 2007-04-18
FR2891827B1 (fr) 2007-12-28
CA2564369A1 (fr) 2007-04-11

Similar Documents

Publication Publication Date Title
AR056573A1 (es) Forma cristalina delta del clohidrato de ivabradina,un procedimiento para su preparacion,composiciones farmaceuticas que la contienen y usos en trastornos cardiovasculares.
AR056572A1 (es) FORMA CRISTALINA ð DEL CLOHIDRATO DE IVABRADINA,UN PROCEDIMIENTO PARA SU PREPARACION,COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN Y USOS EN TRASTORNOS CARDIOVASCULARES.
AR056931A1 (es) Forma cristalina gamma d del clorhidrato de ivabradina, un procedimiento para su preparacion, composiciones farmaceuticas que la contienen, y usos en trastornos cardiovasculares
AR052926A1 (es) Forma cristalina gama del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones que la contienen
CR8247A (es) FORMA CRISTALINA BETA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN
CR8248A (es) Forma cristalina beta del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
BRPI0621446C1 (pt) composição farmacêutica para uso externo
EP2054411A4 (en) NOVEL COMPOUNDS, ISOMERS THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2011023737A3 (en) Reminder device for drug delivery devices
AR057715A1 (es) Forma cristalina v de la agomelatina, un procedimiento para su preparacion, y composiciones farmaceuticas que la contienen
EP1903402A3 (en) Toner and developer
EP1861357A4 (en) NEW COMPOUNDS, ISOMERS THEREOF, OR PHARMACEUTICALLY SALTS SUCH AS VANILLOIDREZEPTORANTAGONIST, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2007092642A3 (en) Polymer formulations of cetp inhibitors
WO2010123919A3 (en) Piperidine inhibitors of janus kinase 3
PT2076244T (pt) Sistemas aquosos para a preparação de compostos farmacêuticos à base de lípidos; composições, métodos e utilizações dos mesmos
BRPI0603043A (pt) forma cristalina iv de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
IL189781A0 (en) Sulphonylpyrrole hydrochloride salts and pharmaceutical compositions containing the same
WO2006090268A3 (en) Processes for the preparation of alfuzosin and salts thereof and novel crystalline forms of alfuzosin
EP2238105A4 (en) NOVEL COMPOUNDS, ISOMERS, OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF, CONTAINING VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS THEREWITH
WO2009063990A1 (ja) ベンズアゼピノン化合物
WO2007120725A3 (en) Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
WO2007026219A3 (en) Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
IL190063A (en) The history of cycloalkanes is preserved, their medicinal preparations and their uses
FR2897608B1 (fr) Materiaux intermetalliques pulverulents pour le stockage reversible de l'hydrogene
WO2007034254A8 (en) Amino-alkyl-amide derivatives as ccr3 receptor ligands

Legal Events

Date Code Title Description
FA Abandonment or withdrawal